Talk:Astellas Institute for Regenerative Medicine
| This is the talk page for discussing improvements to the Astellas Institute for Regenerative Medicine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
Human cloning in 1995?
editAccording to this page, this company successfully cloned a human being in 1995, although it was never allowed to develop past a 32x cell division. Also according to that page, the issue has since been hushed up somewhat, even though it was covered in the mainstream press. This proabably ought to be included in the article, unless it's some kind of tinfoil hat stuff. 161.11.130.249 (talk) 17:48, 8 April 2008 (UTC)
I have followed all news regarding this company very extensively for over four years, and I have never seen any credible information/cites/references on this subject. While anything is possible, this cloning idea seems exceptionally unlikely. Even though the above comment was made several years ago, anybody could still be reading these pages now, so I think it's worthwhile to correct this information. RealAnise (talk) 20:54, 5 April 2015 (UTC)
- Thanks. this is just the talk page. people write things like the comment above, other people write as you did, that there are no sources for it, and that is as far as it goes. the comment was related to the content, so it can stay, per WP:TPG. stuff people write on Talk pages that is just gossip or is otherwise not related to improving the article, can be deleted, however. please do read WP:TPG, Jytdog (talk) 20:57, 5 April 2015 (UTC)
Resources to check for additional topic coverage
editPatents
edit- Patent 5,945,577: Cloning using donor nuclei from proliferating somatic cells —Preceding unsigned comment added by Healthwise (talk • contribs) 13:19, 27 September 2007 (UTC)
id like to see a history section
editid like to see a history section that outlines key events over the course of the company's history. — Preceding unsigned comment added by 76.253.138.62 (talk) 23:05, 16 December 2012 (UTC)
Added Cites for Information About Trials
edit{{request edit|D|V}}
Cite on AMD and SMD trials added to the end of each section.
Also, here's a question: I would like to add that this proposed treatment would also be effective against extremely rare forms of the disease, such as idiopathic macular degeneration. This information comes from a personal conversation with Dr. Andreas Lauer, retinal specialist at Casey Eye Institute (Oregon Health and Science University.) Is there any way to add this information with that kind of cite? I've never seen the information in print or online, and I don't think it actually exists in that form. Thanks! :)
- Macular degeneration
On November 30, 2010, Ocata filed an Investigational New Drug application with the U.S. FDA for the first clinical trial using embryonic stem cells to regenerate retinal pigment epithelium to treat Dry Age-Related Macular Degeneration (Dry AMD).[16] Dry AMD is the most common form of macular degeneration and represents a market size of $25–30 Billion in the U.S. and Europe.[17] More information on the dry AMD trials can be found at [1]
References
- ^ "Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 5 April 2015.
- this content is in the article already... this is actually ok, the IND filing. Jytdog (talk) 22:50, 5 April 2015 (UTC)
- Stargardt's Disease
In November 2010, the FDA allowed Ocata to begin a Phase I/II human clinical trial which uses its retinal pigment epithelium cell therapy to treat Stargardt disease, a form of inherited juvenile macular degeneration.[18] More information on these trials can be found at [1]
References
- ^ "Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 5 April 2015.
--— Preceding unsigned comment added by RealAnise (talk • contribs) 21:46, 5 April 2015 (UTC)
- Hi Please remember to sign your posts ~~~~ OK. please read WP:OR and WP:VERIFY, and then WP:MEDRS. What you will learn after you do that, is that no original research is allowed in WP - all content needs to be verifiable, from reliable sources. OR descibes no original research; VERIFY describes the need for verification, and MEDRS tells you what "counts" as reliable sources, for content about health. Lots to learn, when you want to really get involved with Wikipedia. Jytdog (talk) 22:48, 5 April 2015 (UTC)
Sources about stem cell trials
editneed to flesh out the resarchy stuff better...
- Takahashi, J (2 April 2018). "Stem cells and regenerative medicine for neural repair". Current opinion in biotechnology. 52: 102–108. doi:10.1016/j.copbio.2018.03.006. PMID 29621691.
- Ilic, D; Devito, L; Miere, C; Codognotto, S (2015). "Human embryonic and induced pluripotent stem cells in clinical trials". British medical bulletin. 116: 19–27. doi:10.1093/bmb/ldv045. PMID 26582538.
